Cargando…

(2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds

BACKGROUND: Tuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis. Compounds including a sulfur-containing scaffold have been shown to be key scaffolds in various antituberculosis agents. Interestingly, the 3-hydroxy-3-phenyl-prop-2-enedithioic acids 11a-j have, to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pretelín-Castillo, Gustavo, Silva Miranda, Mayra, Espitia, Clara, Chávez-Santos, Rosa María, Suárez-Castro, Abel, Chacón-García, Luis, Aguayo-Ortiz, Rodrigo, Martinez, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543028/
https://www.ncbi.nlm.nih.gov/pubmed/34707377
http://dx.doi.org/10.2147/IDR.S328132
_version_ 1784589555151667200
author Pretelín-Castillo, Gustavo
Silva Miranda, Mayra
Espitia, Clara
Chávez-Santos, Rosa María
Suárez-Castro, Abel
Chacón-García, Luis
Aguayo-Ortiz, Rodrigo
Martinez, Roberto
author_facet Pretelín-Castillo, Gustavo
Silva Miranda, Mayra
Espitia, Clara
Chávez-Santos, Rosa María
Suárez-Castro, Abel
Chacón-García, Luis
Aguayo-Ortiz, Rodrigo
Martinez, Roberto
author_sort Pretelín-Castillo, Gustavo
collection PubMed
description BACKGROUND: Tuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis. Compounds including a sulfur-containing scaffold have been shown to be key scaffolds in various antituberculosis agents. Interestingly, the 3-hydroxy-3-phenyl-prop-2-enedithioic acids 11a-j have, to the best of our knowledge, not been previously described as antituberculosis agents. PURPOSE: In the present study, we investigated the role of substituents attached to the phenyl ring of a 3-hydroxy-3-phenyl-prop-2-enedithioic acid scaffold (compounds 11a–j) in inhibiting the growth of M. tuberculosis strain H37Rv. METHODS: (Z)-3-hydroxy-3-(4-R-phenyl)-prop-2-enedithioic acids 11b–j, with R groups including various electron-donating or electron-withdrawing groups, were designed by structurally modifying the lead compound 11a. The syntheses of 11a–j involved each one-step procedure starting from the corresponding substituted acetophenone. Compounds 11a–j were tested against M. tuberculosis strain H37Rv to evaluate their bacterial growth inhibitory activities. ADMET profiles were predicted by employing three different methods. In addition, molecular docking studies were carried out, based on the molecular similarities of the synthesized compounds with ethionamide (5), on the active site of the M. tuberculosis H37Rv (3R)-hydroxyacyl-ACP (HadAB) dehydratase heterodimer. RESULTS: The antituberculosis activities of compounds 11a–j could be explained in terms of the presence of electron-donating or electron-withdrawing substituents on the aromatic ring of the substituted 3-hydroxy-3-phenyl)-prop-2-enedithioic acid core. The activity and selectivity index (SI) value of (Z)-3-hydroxy-3-(4-nitrophenyl)-prop-2-enedithioic acid 11e suggested that this compound could be used for the design of novel antituberculosis agents. Most of the synthesized molecules showed an acceptable ADME profile and a low probability of being toxic. Docking studies of 11d and 11e showed them forming hydrogen bonds with the ACys61 residue of the HadAB enzyme. CONCLUSION: Our results suggested that the antituberculosis compound 11e could be used for the design of novel antituberculosis agents.
format Online
Article
Text
id pubmed-8543028
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85430282021-10-26 (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds Pretelín-Castillo, Gustavo Silva Miranda, Mayra Espitia, Clara Chávez-Santos, Rosa María Suárez-Castro, Abel Chacón-García, Luis Aguayo-Ortiz, Rodrigo Martinez, Roberto Infect Drug Resist Original Research BACKGROUND: Tuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis. Compounds including a sulfur-containing scaffold have been shown to be key scaffolds in various antituberculosis agents. Interestingly, the 3-hydroxy-3-phenyl-prop-2-enedithioic acids 11a-j have, to the best of our knowledge, not been previously described as antituberculosis agents. PURPOSE: In the present study, we investigated the role of substituents attached to the phenyl ring of a 3-hydroxy-3-phenyl-prop-2-enedithioic acid scaffold (compounds 11a–j) in inhibiting the growth of M. tuberculosis strain H37Rv. METHODS: (Z)-3-hydroxy-3-(4-R-phenyl)-prop-2-enedithioic acids 11b–j, with R groups including various electron-donating or electron-withdrawing groups, were designed by structurally modifying the lead compound 11a. The syntheses of 11a–j involved each one-step procedure starting from the corresponding substituted acetophenone. Compounds 11a–j were tested against M. tuberculosis strain H37Rv to evaluate their bacterial growth inhibitory activities. ADMET profiles were predicted by employing three different methods. In addition, molecular docking studies were carried out, based on the molecular similarities of the synthesized compounds with ethionamide (5), on the active site of the M. tuberculosis H37Rv (3R)-hydroxyacyl-ACP (HadAB) dehydratase heterodimer. RESULTS: The antituberculosis activities of compounds 11a–j could be explained in terms of the presence of electron-donating or electron-withdrawing substituents on the aromatic ring of the substituted 3-hydroxy-3-phenyl)-prop-2-enedithioic acid core. The activity and selectivity index (SI) value of (Z)-3-hydroxy-3-(4-nitrophenyl)-prop-2-enedithioic acid 11e suggested that this compound could be used for the design of novel antituberculosis agents. Most of the synthesized molecules showed an acceptable ADME profile and a low probability of being toxic. Docking studies of 11d and 11e showed them forming hydrogen bonds with the ACys61 residue of the HadAB enzyme. CONCLUSION: Our results suggested that the antituberculosis compound 11e could be used for the design of novel antituberculosis agents. Dove 2021-10-20 /pmc/articles/PMC8543028/ /pubmed/34707377 http://dx.doi.org/10.2147/IDR.S328132 Text en © 2021 Pretelín-Castillo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Pretelín-Castillo, Gustavo
Silva Miranda, Mayra
Espitia, Clara
Chávez-Santos, Rosa María
Suárez-Castro, Abel
Chacón-García, Luis
Aguayo-Ortiz, Rodrigo
Martinez, Roberto
(2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds
title (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds
title_full (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds
title_fullStr (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds
title_full_unstemmed (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds
title_short (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds
title_sort (2z)-3-hydroxy-3-(4-r-phenyl)-prop-2-enedithioic acids as new antituberculosis compounds
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543028/
https://www.ncbi.nlm.nih.gov/pubmed/34707377
http://dx.doi.org/10.2147/IDR.S328132
work_keys_str_mv AT pretelincastillogustavo 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds
AT silvamirandamayra 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds
AT espitiaclara 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds
AT chavezsantosrosamaria 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds
AT suarezcastroabel 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds
AT chacongarcialuis 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds
AT aguayoortizrodrigo 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds
AT martinezroberto 2z3hydroxy34rphenylprop2enedithioicacidsasnewantituberculosiscompounds